Polidocanol
As of the edition of 20 October 2026, Polidocanol is a small molecule: marketed, first approved in 1982 (ES).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2010
- Kind
- Small molecule
- Brand name
- Asclera
- First approved
- 1 December 1982 (ES)
- Approvals on record
- 7 in 4 regions
- Holder of the most recent approval
- Boston Scientific; 4 holders in all
- Registered trials
- 19, 4 stopped early
- Disease areas
- Heart and blood vessels; Skin and connective tissue; Digestive system; Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 3 | 1 | 1 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 4 | 3 | 0 | 1 |
| Phase 3 | 3 | 3 | 0 | 0 |
| Phase 4 | 6 | 1 | 2 | 2 |
| All trials | 19 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Chemische Fabrik Kreussler | Applicant | 2010 to now |
| Boston Scientific | Acquired holder and Lead sponsor of trials | 2010 to now |